This page shows the latest Taflinar news and features for those working in and with pharma, biotech and healthcare.
all patents regardless of their BRAF status, potentially making it more useful than BRAF inhibitors such as Roche's Zelboraf (vemurafenib) and Novartis' Taflinar (dabrafenib).
inhibitors such as Roche's Zelboraf (vemurafenib) and GSK's Taflinar (dabrafenib).
NICE said the information provided by GSK suggested that Taflinar works as well as Zelboraf, which also targets the BRAF V600 mutations.
However, just as Roche was forced to discount Zelboraf's price before NICE recommended it, the new Taflinar guidance was only issued on the basis GSK discount its drug's list ... Taflinar was approved in Europe in August 2013, based on phase III results
Regulatory advisors recommend the melanoma drug be licensed
More from news
Approximately 2 fully matching, plus 3 partially matching documents found.
Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...